PharmaSGP (PSG) Q3 2024 earnings summary

Executive summary

• Revenue grew 17.0% year-over-year to €88.6 million in the first nine months of 2024, driven by strong performance in core brands and international markets.

• Adjusted EBITDA increased by 9.4% to €27.0 million, with a margin of 30.5%, though the margin declined by 2.2 percentage points due to higher marketing and operating expenses.

• Profit for the period rose to €14.1 million, up from €11.6 million in the prior year, with EPS at €1.17.

Financial highlights

• Revenues: €88.6 million (9M 2024), up 17.0% from €75.7 million (9M 2023).

• Adjusted EBITDA: €27.0 million, up 9.4% year-over-year; margin at 30.5%.

• EBIT: €19.9 million (9M 2024) vs. €17.7 million (9M 2023).

• Net profit: €14.1 million, up from €11.6 million; EPS €1.17 vs. €0.97.

• Cash and cash equivalents at €37.8 million as of 30 September 2024.

Outlook and guidance

• Revenue guidance for FY 2024 raised to €112.0–117.0 million.

• Adjusted EBITDA expected between €35.0–38.0 million, with a margin of 31.3–32.5%.